3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Pancreatic Neoplasms
2
Melanoma
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Infertility
1
Hereditary Sensory and Autonomic Neuropathies
1
Glioma
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Diseases
1
Interventions
selpercatinib
2
pembrolizumab
2
abemaciclib
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Fulvestrant
2
Abiraterone Acetate
2
ribociclib
1
repotrectinib
1
relatlimab
1
pralsetinib
1
pamiparib
1
palbociclib
1
osimertinib
1
onapristone
1
olaparib
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
exemestane
1
enzalutamide
1
elacestrant
1
cobimetinib
1
abiraterone
1
Trastuzumab
1
Taxes
1
Tamoxifen
1
STX-478
1
Radiation
1
RAD1901
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms by Site
×
Metformin
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled